PIK3CD and cancer: Considering that MTAs are widely used in treating many solid cancers, and given the heterogeneous biology of cancers, future studies could aim to identify biomarkers and combinatorial regimes for stratified treatment with PI3K inhibitors and MTAs in different cancers at different stages.